-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Hold on Pliant Therapeutics, Lowers Price Target to $3

Benzinga·03/13/2026 18:27:35
Listen to the news
Canaccord Genuity analyst Edward Nash maintains Pliant Therapeutics (NASDAQ:PLRX) with a Hold and lowers the price target from $4 to $3.